TNGX Tango Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why TNGX matters now
Tango Therapeutics, Inc. (TNGX) is a US stock in Healthcare. The latest InvestLog snapshot shows $30.52 with -0.39% on the session and $3.80B in market capitalization; recent performance reads 1-month +37.78% and YTD +215.69%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-45.5M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.1%.
The latest indexable market news headline is "Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.00; recent insider activity includes Lee Sung filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.26
P/S
61.07
EV/EBITDA
-31.91
DCF Value
$-13.83
FCF Yield
-4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.3%
Operating Margin
-206.2%
Net Margin
-188.2%
ROE
-41.5%
ROA
-24.6%
ROIC
-27.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-45.5M | $-0.32 |
| Q4 2025 | $0.00 | $-38.7M | $-0.30 |
| FY 2025 | $62.4M | $-101.6M | $-0.87 |
| Q3 2025 | $53.8M | $15.9M | $0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$42.70
Target (Median)
$38.00
Target Range
$24.00 - $69.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.19
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.